User:Mr. Ibrahem/Gemifloxacin

Mr. Ibrahem/Gemifloxacin
Clinical data
Other names	Gemifloxacin mesylate
AHFS/Drugs.com	Monograph
MedlinePlus	a604014
Pregnancy; category	C;
Routes of; administration	By mouth
Drug class	Fluoroquinolone
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	71%
Protein binding	60–70%
Metabolism	Limited metabolism by the liver to minor metabolites
Excretion	Feces (61%); urine (36%)
Identifiers
	IUPAC name 7-[(4Z)-3-(Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo- 1,8-naphthyridine-3-carboxylic acid;
Chemical and physical data
Formula	C18H20FN5O4
Molar mass	389.387 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc2c(nc1N(/C=C(/C(=O)O)C(=O)c1c2)C3CC3)N4C/C(=N\OC)C(C4)CN;
	InChI InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+ ; Key:ZRCVYEYHRGVLOC-HYARGMPZSA-N ;
	(what is this?) (verify)

Gemifloxacin, sold under the brand name Factive, is an antibiotic used to treat COPD exacerbations and mild-to-moderate pneumonia.^[1] It may also be used for gonorrhea.^[2] It is generally only used when other options are not suitable.^[1] It is taken by mouth.^[1]

Common side effects include diarrhea, nausea, rash, headache, and abdominal pain.^[1] Other side effects may include tendon rupture, prolonged QT, anaphylaxis, peripheral neuropathy, psychosis, and Clostridioides difficile infection.^[3] There are concerns that use in pregnancy may harm the baby.^[1] It is in the fluoroquinolone family.^[1]

Gemifloxacin was approved for medical use in the United States in 2003.^[1] In the United States 5 tablets of 320 mg costs about 220 USD as of 2021.^[4] There; however, has been a shortage of the medication due to a dispute over the right to manufacture it, which has been ongoing since 2015.^[5]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Gemifloxacin Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 3 December 2021.
^ Canada, Public Health Agency of (28 July 2017). "Treatment of N. gonorrhoeae in response to the discontinuation of spectinomycin". www.canada.ca. Archived from the original on 1 October 2021. Retrieved 3 December 2021.
^ "DailyMed - FACTIVE- gemifloxacin mesylate tablet". dailymed.nlm.nih.gov. Archived from the original on 21 December 2016. Retrieved 3 December 2021.
^ "Factive Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 3 December 2021.
^ "FDA Drug Shortages". www.accessdata.fda.gov. Archived from the original on 29 April 2021. Retrieved 3 December 2021.

[AHFS2021-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Gemifloxacin Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 3 December 2021.

[Can2017-2] Canada, Public Health Agency of (28 July 2017). "Treatment of N. gonorrhoeae in response to the discontinuation of spectinomycin". www.canada.ca. Archived from the original on 1 October 2021. Retrieved 3 December 2021.

[PI2021-3] "DailyMed - FACTIVE- gemifloxacin mesylate tablet". dailymed.nlm.nih.gov. Archived from the original on 21 December 2016. Retrieved 3 December 2021.

[4] "Factive Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 3 December 2021.

[FDA2021Short-5] "FDA Drug Shortages". www.accessdata.fda.gov. Archived from the original on 29 April 2021. Retrieved 3 December 2021.

[1]

[2]

[3]

[4]

[5]